ArticleScientific reports2025
Altered microRNA profiles and associated pathways in canine mammary adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcriptomic and microRNA Profiling Suggest a Candidate RIPPLY1-cfa-miR-187 Relationship in Canine Mammary Gland Tumours From Dogs With Confirmed Metastasis.Veterinary and comparative oncology · 2026Article
- The role of epigenetic alterations in canine mammary cancer.The Journal of reproduction and development · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Canine mammary tumors (CMTs) are common in female dogs and represent a key model for studying human breast cancer (BC). Among the various subtypes of CMT, adenocarcinoma of the mammary gland (AMG) is one of the most prevalent and aggressive. In this study, we analyzed the expression of 84 microRNAs (miRNAs) in AMG and healthy mammary tissues using qRT-PCR. MiRNA profiling in canine AMG tissue revealed upregulation of miR-101, miR-106b, miR-143, miR-15a, miR-205, and miR-93, and downregulation of let-7c, miR-10b, miR-191, and miR-26a. Pathway enrichment linked these deregulated miRNAs to key oncogenic networks, particularly PI3K/AKT/mTOR, Wnt/β-catenin, and EMT regulation, demonstrating conserved molecular mechanisms shared with human BC and highlighting their potential as biomarkers in CMTs. These findings provide insights into the molecular mechanisms of CMT adenocarcinoma and suggest the potential of miRNA-based biomarkers for the diagnosis and treatment of CMTs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.